News | Imaging Software Development | April 15, 2025

FDA Grants Clearance for AI-powered Cardiac Imaging Software 

The milestone signals a new era of access for cardiac care, enabling any healthcare professional to perform diagnostic-grade echos anytime, anywhere. 

HeartFlow

April 15, 2025 – DESKi recently announced FDA clearance for HeartFocus, its AI-enabled heart exam software that empowers any healthcare professional, including novices, to perform clinical-quality heart scans from any compatible device after just a few hours of training. 

The FDA also approved DESKi’s Predetermined Change Control Plan (PCCP) for HeartFocus’ growth opportunities. This clears the way for faster collaboration with other ultrasound systems, so the technology can reach more patients sooner. 

“Heart disease is the number one killer worldwide, and echocardiography is the first step to receiving a diagnosis and proper treatment. However, there is a critical shortage of cardiologists and expert sonographers to meet demand. HeartFocus bridges that gap, empowering any healthcare provider, anywhere, to capture cardiac images with precision and confidence,” said Bertrand Moal, PhD, MD, CEO of DESKi. “This clearance affirms our technology and accelerates our ability to bring earlier diagnosis and life-saving care to all who need it, including rural and underserved communities.”

The efficacy of HeartFocus was validated in a landmark international clinical trial conducted in partnership with Northwell Health in the United States and the University Hospital of Bordeaux (CHU) in France. In a blind review, 100% of novice-conducted scans using HeartFocus met diagnostic standards for all primary endpoints and were comparable to those completed by expert sonographers. 

“The clinical trial results and subsequent FDA clearance mark a major step forward in making echocardiography more accessible in the community,” said Dr. Varinder P. Singh, SVP, Global and International Health, Northwell. “Proving that it can successfully guide any healthcare professional to capture high-quality heart scans, HeartFocus will help patients get diagnosed sooner and move more quickly toward the treatment they need.”

“HeartFocus is opening the door to a new era in cardiac imaging,” said Stéphane Lafitte, Professor of Cardiology at CHU de Bordeaux. “We’ve proven that AI can empower novices to reliably perform echocardiograms, a breakthrough that could reshape how we diagnose and treat heart disease. It’s an exciting advancement for the field of cardiology, with the potential to extend high-quality care to more patients globally than ever before.”

For more information, visit www.heartfocus.ai


Related Content

News | FDA

Jan. 13, 2026 – Innovative Health, Inc. has received its 50th clearance from FDA to reprocess single-use medical devices ...

Home January 15, 2026
Home
News | FDA

Jan. 12, 2026 — HeartLung Corp. has announced U.S. Food and Drug Administration (FDA) clearance of AI-CVD, its AI ...

Home January 12, 2026
Home
News | FDA

Jan. 6, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the FDA approval of the Gore Viabahn ...

Home January 06, 2026
Home
News | FDA

Dec. 22, 2025 — Abbott recently announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt ...

Home January 05, 2026
Home
News | FDA

Dec. 18, 2025 — Huxley Medical has announced the SANSA home sleep apnea test has received regulatory clearance from the ...

Home December 19, 2025
Home
News | FDA

Dec. 18, 2025 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer ...

Home December 18, 2025
Home
News | FDA

Dec. 15, 2025 — HeartSciences Inc., a healthcare information technology company advancing the use of ECG/EKGs through ...

Home December 16, 2025
Home
News | FDA

Nov. 25, 2025 — Remington Medical has received U.S. Food and Drug Administration (FDA) 510(k) clearance and announced ...

Home December 09, 2025
Home
News | FDA

Dec. 3, 2025 — Atraverse Medical, a medical device company developing next-generation left-heart access technology, has ...

Home December 05, 2025
Home
News | FDA

Dec.1, 2025 – MannKind Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA ...

Home December 01, 2025
Home
Subscribe Now